

Jeffrey Newcorn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1913587/publications.pdf>

Version: 2024-02-01

23
papers

1,217
citations

623188

14
h-index

752256

20
g-index

25
all docs

25
docs citations

25
times ranked

1231
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptom Profiles in Children With ADHD: Effects of Comorbidity and Gender. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2001, 40, 137-146.	0.3	347
2	Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response. <i>American Journal of Psychiatry</i> , 2008, 165, 721-730.	4.0	294
3	Atomoxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 240-248.	0.3	154
4	Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 511-518.	0.3	72
5	Randomized, Double-Blind Trial of Guanfacine Extended Release in Children With Attention-Deficit/Hyperactivity Disorder: Morning or Evening Administration. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 921-930.	0.3	49
6	Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 1165-1172.	0.3	35
7	Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency. <i>Addiction</i> , 2015, 110, 784-795.	1.7	33
8	Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2017, 31, 999-1014.	2.7	33
9	Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder. <i>Pediatrics</i> , 2006, 118, e1701-e1706.	1.0	30
10	Dose-Response Characteristics in Adolescents with Attention-Deficit/Hyperactivity Disorder Treated with OROS [®] Methylphenidate in a 4-Week, Open-Label, Dose-Titration Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 187-196.	0.7	26
11	Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised withdrawal maintenance of efficacy study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2016, 57, 717-728.	3.1	26
12	SNP genotyping using TaqMan [®] technology: the CYP2D6*17 assay conundrum. <i>Scientific Reports</i> , 2015, 5, 9257.	1.6	24
13	Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 602-609.e2.	0.3	21
14	A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). <i>CNS Drugs</i> , 2018, 32, 289-301.	2.7	19
15	A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). <i>CNS Drugs</i> , 2021, 35, 1035-1051.	2.7	16
16	Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: A pilot fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2015, 231, 353-356.	0.9	9
17	New treatments and approaches for attention deficit hyperactivity disorder. <i>Current Psychiatry Reports</i> , 2001, 3, 87-91.	2.1	8
18	Long-Term Treatment With Extended-Release Methylphenidate Treatment in Children Aged 4 to <6 Years. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, , .	0.3	8

#	ARTICLE	IF	CITATIONS
19	Comorbidity of ADHD and anxiety disorders. , 2014, , 98-110.		5
20	Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 2019, 29, 432-443.	0.3	5
21	Can Children With Callous and Unemotional Traits Be Treated Successfully?. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 1257-1259.	0.3	1
22	Medication for ADHD and accidental injury. Lancet Psychiatry,the, 2015, 2, 669-671.	3.7	1
23	Recent Progress in Psychosocial and Psychopharmacologic Treatments for ADHD. Current Treatment Options in Psychiatry, 2015, 2, 14-27.	0.7	1